Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Aslan Pharmaceuticals Ltd ADR (NQ: ASLN ) 0.4100 +0.0089 (+2.22%) Streaming Delayed Price Updated: 3:54 PM EDT, Jun 14, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 214,266 Open 0.4200 Bid (Size) 0.4000 (96) Ask (Size) 0.4300 (2) Prev. Close 0.4011 Today's Range 0.4001 - 0.4302 52wk Range 0.3920 - 4.230 Shares Outstanding 402,116,835 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change June 14, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire ASLAN Pharmaceuticals Presents Late-Breaking Translational Data on Eblasakimab in COPD at the American Thoracic Society International Conference May 21, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire Performance YTD -25.45% -25.45% 1 Month +2.50% +2.50% 3 Month -36.92% -36.92% 6 Month -29.07% -29.07% 1 Year -89.72% -89.72% More News Read More ASLN Stock Earnings: ASLAN Pharma Beats EPS for Q1 2024 May 09, 2024 Via InvestorPlace ASLAN Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update May 09, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire ASLAN Pharmaceuticals to Present Additional Data From Interim Analysis of TREK-DX Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients During Virtual KOL Event May 07, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire ASLAN Pharmaceuticals Announces Expansion of its Collaboration With Zenyaku to Investigate the Biology Underlying Differential Effects of Eblasakimab Compared to Other Biologics May 02, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab April 30, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire 12 Health Care Stocks Moving In Friday's After-Market Session April 26, 2024 Via Benzinga ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference April 24, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients April 22, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice April 19, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire ASLN Stock Earnings: ASLAN Pharma Misses EPS for Q4 2023 April 12, 2024 Via InvestorPlace ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update April 12, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders March 27, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire Week In Review: Under Pressure From US Congress, WuXi AppTec Resigns From BIO March 16, 2024 Via Talk Markets ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering March 12, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Intraday Session March 11, 2024 Via Benzinga ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients March 11, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's Pre-Market Session March 06, 2024 Via Benzinga ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors March 06, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat February 29, 2024 From ASLAN PHARMACEUTICALS LIMITED Via GlobeNewswire 12 Health Care Stocks Moving In Monday's Intraday Session February 05, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session January 17, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's After-Market Session January 16, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Intraday Session January 16, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
